Table 3.
Iron
|
Mebendazole
|
||||
---|---|---|---|---|---|
Placebo (n=176) | Treatment (n=183) | Placebo (n=182) | Treatment (n=177) | ||
Mean (SD) haemoglobin (g/l): | |||||
Baseline | 86 (15) | 86 (15) | 86 (15) | 85 (15) | |
12 months | 97 (16) | 99 (15) | 99 (15) | 98 (16) | |
Haemoglobin <110 g/l: | |||||
Baseline | 169 (96) | 178 (97) | 174 (96) | 173 (98) | |
12 months | 142 (81) | 144 (79) | 147 (81) | 139 (79) | |
Haemoglobin <70 g/l: | |||||
Baseline | 26 (15) | 28 (15) | 21 (12) | 33 (19) | |
12 months | 8 (5) | 5 (3) | 6 (3) | 7 (4) | |
Mean erythrocyte protoporphyrin (μmol/mol): | |||||
Baseline* | 153 | 162 | 155 | 160 | |
12 months | 86 | 72† | 76 | 80 | |
Mean serum ferritin (μg/l): | |||||
Baseline* | 29.2 | 32.5 | 30.9 | 30.8 | |
12 months | 45.8 | 60.8‡ | 58.1 | 47.9§ |
Geometric mean.
Iron v placebo, P=0.032.
Iron v placebo, P=0.002.
Mebendazole v placebo, P=0.037.